Sichuan Hebang Biotechnology Corporation Limited

SHSE:603077 Rapporto sulle azioni

Cap. di mercato: CN¥16.5b

Sichuan Hebang Biotechnology Crescita futura

Future criteri di controllo 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Sichuan Hebang Biotechnology.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Chemicals crescita degli utili38.3%
Tasso di crescita dei ricavin/a
Rendimento futuro del capitale proprion/a
Copertura analitica

None

Ultimo aggiornamenton/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Returns On Capital At Sichuan Hebang Biotechnology (SHSE:603077) Have Stalled

Sep 25
Returns On Capital At Sichuan Hebang Biotechnology (SHSE:603077) Have Stalled

Sichuan Hebang Biotechnology Corporation Limited's (SHSE:603077) Shares Not Telling The Full Story

Aug 16
Sichuan Hebang Biotechnology Corporation Limited's (SHSE:603077) Shares Not Telling The Full Story

Return Trends At Sichuan Hebang Biotechnology (SHSE:603077) Aren't Appealing

Jun 04
Return Trends At Sichuan Hebang Biotechnology (SHSE:603077) Aren't Appealing

Investors Holding Back On Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077)

May 13
Investors Holding Back On Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077)

Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?

Mar 07
Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?

Here's Why I Think Sichuan Hebang Biotechnology (SHSE:603077) Is An Interesting Stock

Apr 21
Here's Why I Think Sichuan Hebang Biotechnology (SHSE:603077) Is An Interesting Stock

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Sichuan Hebang Biotechnology non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

SHSE:603077 - Stime future degli analisti e dati finanziari passati (CNY Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
9/30/20249,203486-933-205N/A
6/30/20249,582859-1,159-362N/A
3/31/20248,429916-1,572-700N/A
12/31/20238,8241,283-74880N/A
9/30/20238,9801,398272886N/A
6/30/20239,6511,7895751,246N/A
3/31/202312,3473,1611,5412,383N/A
12/31/202213,0393,8071,7082,644N/A
9/30/202213,3534,4387732,970N/A
6/30/202213,5174,7411,6823,670N/A
3/31/202211,4093,8151,5353,537N/A
12/31/20219,9873,0181,4623,271N/A
9/30/20218,4942,2481,9752,627N/A
6/30/20216,7689081,2761,829N/A
3/31/20215,902319685843N/A
12/31/20205,26141172369N/A
9/30/20205,115-147-30779N/A
6/30/20205,351264-57213N/A
3/31/20205,565372-66811N/A
12/31/20195,969517-500163N/A
9/30/20196,200380-243378N/A
6/30/20196,15438740488N/A
3/31/20196,285426537954N/A
12/31/20186,009363581944N/A
9/30/20185,990622574967N/A
6/30/20185,625535N/A1,005N/A
3/31/20184,961395N/A378N/A
12/31/20174,738518N/A177N/A
9/30/20174,400477N/A189N/A
6/30/20174,041451N/A247N/A
3/31/20173,722436N/A270N/A
12/31/20163,463318N/A575N/A
9/30/20163,206260N/A558N/A
6/30/20162,954226N/A248N/A
3/31/20163,043255N/A548N/A
12/31/20152,863240N/A449N/A
9/30/20152,757144N/A173N/A
6/30/20152,628135N/A325N/A
3/31/20152,282679N/A-9N/A
12/31/20142,186672N/A205N/A
9/30/20141,979715N/A-20N/A
6/30/20141,871696N/A-172N/A
3/31/20141,66054N/A-121N/A
12/31/20131,60364N/A-407N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Insufficient data to determine if 603077's forecast earnings growth is above the savings rate (2.9%).

Guadagni vs Mercato: Insufficient data to determine if 603077's earnings are forecast to grow faster than the CN market

Guadagni ad alta crescita: Insufficient data to determine if 603077's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: Insufficient data to determine if 603077's revenue is forecast to grow faster than the CN market.

Ricavi ad alta crescita: Insufficient data to determine if 603077's revenue is forecast to grow faster than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if 603077's Return on Equity is forecast to be high in 3 years time

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y